Lineage Cell Therapeutics(LCTX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE • 24 Month Visual Acuity Benefits from a Single Administration with OpRegen ® Reported at 2024 Retinal Cell & Gene Therapy Innovation Summit • Supported OpRegen for Geographic Atrophy in Phase 2a Study in Collaboration with Roche and Genentech • Initiated Activities Under Recently Established Services Agreement with Genentech to Support Ongoing Development of OpRegen Program • OPC1 Clinical Stud ...